Parkinson’s disease psychosis

References

• Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology. 1993;43(11):2227–2229.
   PubMed Web of Science ®Google Scholar
• Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: A prospective population-based long-term study. Neurology. 2010;75(14):1270–1276.
   PubMed Web of Science ®Google Scholar
• Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Visual symptoms in Parkinson’s disease and Parkinson’s disease dementia. Mov Disord. 2011;26(13):2387–2395.
   PubMed Web of Science ®Google Scholar
• Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology. 2003;60: 1756–1761.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of “benign hallucinations” in Parkinson disease. Arch Neurol. 2006;63(5):713–716.
   PubMedGoogle Scholar
• Rana AQ, Siddiqui I, Zangeneh M, Fattah A, Awan N, Yousuf MS. Predicting treatment-seeking for visual hallucinations among Parkinson’s disease patients. Psychiatry Clin Neurosci. 2013;67(7):509–516.
   PubMed Web of Science ®Google Scholar
• Georgiev D, Danieli A, Ocepek L, et al. Othello syndrome in patients with Parkinson’s disease. Psychiatr Danub. 2010;22(1):94–98.
   PubMed Web of Science ®Google Scholar
• Graff-Radford J, Ahlskog JE, Bower JH. Dopamine agonists and Othello’s syndrome. Parkinsonism Relat Disord. 2010;16(10):680–682.
   PubMed Web of Science ®Google Scholar
• Flann S, Shotbolt J, Kessel B, et al. Three cases of delusional parasitosis caused by dopamine agonists. Clin Exp Dermatol. 2010;35(7):740–742.
   PubMed Web of Science ®Google Scholar
• Kiziltan G, Ozekmekçi S, Ertan S, Ertan T, Erginöz E. Relationship between age and subtypes of psychotic symptoms in Parkinson’s disease. J Neurol. 2007;254(4):448–452.
   PubMed Web of Science ®Google Scholar
• Fenelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson’s disease-associated psychosis: a Cross-sectional study based on the New NINDS-NIMH criteria. Mov Disord. 2010;25(6):763–766.
   PubMed Web of Science ®Google Scholar
• Fenelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010;289(1–2):12–17.
   PubMed Web of Science ®Google Scholar
• Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. J Neurol. 2010;257(7):1073–1082.
   PubMed Web of Science ®Google Scholar
• Rabey JM. Hallucinations and psychosis in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15 suppl 4:S105–S110.
   Google Scholar
• Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NIND, NIMH work group. Mov Disord. 2007;22:1061–1068.
   PubMed Web of Science ®Google Scholar
• Morgante L, Colosimo C, Antonini A, et al. Psychosis associated to Parkinson’s disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry. 2012;83:76–82.
   PubMed Web of Science ®Google Scholar
• Factor SA, Steenland NK, Higgins DS, et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson’s disease. Mov Disord. 2011;26(12):2190–2195.
   PubMed Web of Science ®Google Scholar
• Zhou MZ, Gan J, Wei YR, Ren XY, Chen W, Liu ZG. The association between non-motor symptoms in Parkinson’s disease and age at onset. Clin Neurol Neurosurg. 2013;115(10):2103–2107.
   PubMed Web of Science ®Google Scholar
• Yoritaka A, Shimo Y, Takanashi M, et al. Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: Prevalence and risks. Parkinsonism Relat Disord. 2013;19:725–731.
   PubMed Web of Science ®Google Scholar
• Leroi I, Pantula H, McDonald K, Harbishettar V. Neuropsychiatric symptoms in Parkinson’s disease with mild cognitive impairment and dementia. Parkinsons Dis. 2012;2012:308097.
   PubMed Web of Science ®Google Scholar
• Mack J, Rabins P, Anderson K, et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry. 2012;20(2):123–132.
   PubMed Web of Science ®Google Scholar
• Lee AH, Weintraub D. Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov disord. 2012;27(7):858–863.
   PubMed Web of Science ®Google Scholar
• Munholz RP, Espay AJ, Morgante F, et al. Long-duration Parkinson’s disease: role of lateralization of motor features. Parkinsonism Relat Disord. 2013;19(1):77–80.
   PubMed Web of Science ®Google Scholar
• Sawada H, Oeda T, Yamamoto K, et al. Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol. 2013;13:145.
   PubMed Web of Science ®Google Scholar
• Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine agonists and their risk to induce psychotic episodes in Parkinson’s disease: a case-control study. BMC Neurol. 2009;9(1):23.
   PubMedGoogle Scholar
• Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurol. 2006;66:93–98.
   PubMed Web of Science ®Google Scholar
• Ravina B, Marek K, Eberly S, et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson’s disease. Mov disord. 2012;27(11):1392–1397.
   PubMed Web of Science ®Google Scholar
• Huot P, Fox SH. The serotonergic system in motor and non-motor manifestations of Parkinson’s disease. Exp Brain Res. 2013;230: 463–476.
   PubMed Web of Science ®Google Scholar
• Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318:121–134.
   PubMed Web of Science ®Google Scholar
• Marras C, Kopp A, Qiu F, et al. Antipsychotic use in older adults with Parkinson’s disease. Mov Disord. 2007;22:319–323.
   PubMedGoogle Scholar
• Widge AS, Agarwal P, Giroux M, Farris S, Kimmel RJ, Hebb AO. Psychosis from subthalamic nucleus deep brain stimulator lesion effect. Surg Neurol Int. 2013;4:7.
   PubMedGoogle Scholar
• Smith DJ, Langan J, McLean G, Guthrie B, Mercer SW. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open. 2013;3(4).
   Web of Science ®Google Scholar
• Llebaria G, Pagonabarraga J, Martinez-Corral M, et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson’s disease. Mov Disord. 2010;25(16):2785–2791.
   PubMed Web of Science ®Google Scholar
• Lewis SJG, Shine JM, Duffy S, Halliday G, Naismith SL. Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson’s disease. Mov Disord. 2012;27(10):1262–1267.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson’s disease. Mov Disord. 2005;20:104–115.
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(S3):S42–S80.
   PubMed Web of Science ®Google Scholar
• Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol. 2006;29(6):331–337.
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22:313–318.
   PubMed Web of Science ®Google Scholar
• Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat. 2009;5:327–332.
   PubMed Web of Science ®Google Scholar
• Tagai K, Nagata T, Shinagawa S, Tsuno N, Ozone M, Nakayama K. Mirtazapine improved visual hallucinations in Parkinson’s disease: a case report. Psychogeriatrics. 2013;13(2):103–107.
   PubMed Web of Science ®Google Scholar
• Andersen K, Balldin J, Gottfries CG, et al. A double-blind evaluation of electroconvulsive therapy in Parkinson’s disease with “on-off” phenomena. Acta Neurol Scand. 1987;76(3):191–199.
   PubMed Web of Science ®Google Scholar
• Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT. 2010;26(2):111–115.
   PubMed Web of Science ®Google Scholar
• Usui C, Hatta K, Doi N, et al. Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog NeuroPsychopharmacol Biol Psychiatry. 2011;35:1704–1708.
   PubMed Web of Science ®Google Scholar
• Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson’s disease. Arch Neurol. 2010;67: 416–421.
   PubMed Web of Science ®Google Scholar
• Friedman JH. Pimavanserin for the treatment of Parkinson’s disease psychosis. Expert Opin Pharmacother. 2013;14(14):1969–1975.
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomized, placebo-controlled phase 3 trial. Lancet. Epub October 31, 2013.
   Google Scholar
• Lan CC, Su TP, Chen YS, Bai YM. Treatment dilemma in comorbidity of schizophrenia and idiopathic Parkinson’s disease. Gen Hosp Psychiatry. 2011;33(4):411.
   Web of Science ®Google Scholar
• Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [homepage on the Internet]. Arlington: American Psychiatric Association; 2013. Available from: dsm.psychiatryonline.org. Accessed June 1, 2013.
   Google Scholar